2020-06-01
Pharmacogenomic response of low dose haloperidol in critically ill adults with delirium
Publication
Publication
Journal of Critical Care: improving patient care by integrating critical care systems knowledge into practice behavior , Volume 57 p. 203- 207
Purpose: To characterize the pharmacogenomic response of low-dose haloperidol for delirium treatment in critically ill adults. Materials and methods: Single-center, pilot study of a convenience sample of ICU adults with delirium treated with low-dose IV haloperidol. Patients were evaluated for delirium with the ICDSC every 8 h. Serum haloperidol concentrations were collected on ICU days 2–6, CYP2D6 and CYP3A4 genotypes were characterized and patients were categorized as extensive (EM), intermediate (IM) or poor metabolizers (PM). Results: The 22 patients (median age 67 [IQR 48,77] years; median APACHE III 81[IQR 54,181]; CYP2D6 [EM = 12, IM = 7, PM = 3], CYP3A [EM = 18, IM = 4]) received a median [IQR] daily haloperidol dose of 3.0 [2.4, 4.5] mg. After adjusting for age, SOFA, and ICU day, neither an association between CYP2D6 (IM p = .67/PM p = .25) or CYP3A4 (IM p = .44) metabolizer status and serum haloperidol concentrations was found. After adjusting for age, SOFA, and ICU day, neither an association between daily haloperidol dose (p = .77) or ICDSC score (p = .13) and serum haloperidol concentrations was found. No patient experienced QTc interval prolongation (≥500 ms). Conclusions: This pilot study, the first to evaluate the pharmacogenomic response of low-dose haloperidol when used to treat delirium in the ICU, suggests CYP2D6/CYP3A4 metabolizer status does not affect the serum haloperidol concentrations.
Additional Metadata | |
---|---|
, , , , , | |
doi.org/10.1016/j.jcrc.2020.03.001, hdl.handle.net/1765/125718 | |
Journal of Critical Care: improving patient care by integrating critical care systems knowledge into practice behavior | |
Organisation | Department of Intensive Care |
Trogrlić, Z., van der Jagt, M., Osse, R. J., Devlin, J.W. (John W.), Nieboer, D., Koch, B., … Hunfeld, N. (2020). Pharmacogenomic response of low dose haloperidol in critically ill adults with delirium. Journal of Critical Care: improving patient care by integrating critical care systems knowledge into practice behavior, 57, 203–207. doi:10.1016/j.jcrc.2020.03.001 |